Humacyte Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Humacyte Inc's ROI in the second quarter of 2026?
Humacyte Inc recorded a cumulative net loss of $-97 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -101.44%.

Within the Healthcare sector 623 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3346 to 4063.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-6.65 %	-8.61 %	1.89 %	-19.25 %	-20.18 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	123	94	98	66	118
Return On Investment (TTM)	-101.44 %	-103.82 %	-38.51 %	-38.84 %	-57.42 %
HUMA's Overall Ranking	# 4063	# 3346	# 3262	# 3061	# 3043
Seq. Investment Change TTM	1.44 %	-11.35 %	11.41 %	-6.83 %	-0.68 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-97	-98	-41	-37	-59

HUMA Company Profile >> Back to HUMA Roi Comparisons >> See Annual HUMA Return On Investment

Return On Investment HUMA's Ranking
Within:	No.
Industry	# 104
Sector	# 624
Overall	# 4063

Return On Investment Statistics
High	Average	Low
13.7 %	-62.86 %	-142.88 %
(Sep 30 2022)		(Dec 31 2024)

News about Humacyte Inc Return on Investment ROI

Innovative Breakthrough: HAV's Vascular Trauma Treatment Gains FDA Priority Review, Surges Share Price

February 9, 2024

Human Acellular Vessel (HAV) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine, this brings the share price to 41.22% in the past 90 days.
In a significant milestone for vascular trauma treatment, the Human Acellular Vessel (HAV) has been granted priority review by the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA). The HAV, a groundbreaking medical innovation developed to address the complex challenges of vascular trauma, has shown promising results in a Phase 2/3 clinical trial and through its real-world usage under a Humanitarian Aid Program, specifically in treating wartime trauma injuries in Ukraine.

Financial Statements
Humacyte Inc's II. Quarter Investments	$ 123 Millions	HUMA's Balance sheet
Humacyte Inc's II. Quarter Income	$ -37 Millions	Quarterly HUMA's Income Statement
HUMA's Income by Division		See HUMA's Income by Division

HUMA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	98	118	110	185	275
Y / Y Investment Growth	-16.9 %	7.41 %	-40.57 %	-32.95 %	275.32 %
Net Income in Millions	-41	-149	-111	-12	-26
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-41.67 %	-126.11 %	-100.91 %	-6.48 %	-9.61 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HUMA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HUMA's Competitors
Subscribers only: Roi for Humacyte Inc's Suppliers
Subscribers only: Return On Investment for HUMA's Customers

Other Ratios
HUMA's Roa	HUMA's Inventory Turnover Ratio	HUMA's Growth Rates	HUMA's Dividend Statistics
	HUMA's Profitability Ratios	HUMA's Asset Turnover Ratio	HUMA's Dividend Growth
HUMA's Roe	HUMA's Valuation Ratios	HUMA's Financial Strength Ratios	HUMA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:40:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.